Tumax Deepwise Recognized as One of MIT Technology Review's 50 Smartest Companies, Files IPO Prospectus

On June 29, the Global Smart Companies Summit was held in Hangzhou, where the “MIT Technology Review 50 Smartest Companies List (TR50)” was officially unveiled. Leveraging its technological innovation and commercialization capabilities in the field of intelligent healthcare, Tuma Shenwei stood out from the competition and was named one of MIT Technology Review’s 50 Smartest Companies!

Zhong Xin, Founder and CEO of Tuma Deepwise, Takes the Stage to Accept the Award

Tumashenwei was named one of the “50 Smartest Companies” for the following reason: The sensitivity of result interpretation in its multiple intelligent diagnostic systems has surpassed that of most radiologists, while maintaining a low false-positive rate, making it one of the leading products globally in its category.

Keywords: 97%

—The pulmonary nodule diagnosis system achieves a detection rate of over 97% in real-world scenarios, with a concordance rate exceeding 90% in distinguishing between benign and malignant nodules.

How to Define a “Smart” Company? As MIT Technology Review puts it, this may sound difficult, but you will know it when you see one. When such a company commercializes a truly innovative technology, something remarkable happens: the market leader’s position is either consolidated or displaced by another company, and competitors must redefine or rethink their strategies.

Since 2010, MIT Technology Review has annually selected the “50 Smartest Companies.” The core of this ranking is not short-term revenue figures, but rather the capacity for innovation based on emerging technologies: whether a company has made significant innovations in the past year that will redefine its field.

From the companies on the list, “AI” is nearly ubiquitous. The resulting technological evolution and innovation in computing power, cloud infrastructure, chips, and other areas have further given rise to an entirely new “AI civilization.” Companies such as Alibaba Cloud, Qualcomm, NVIDIA, and iFlytek are included on the list, alongside emerging AI enterprises like Heren Technology, Squirrel AI, SenseTime, and Yitu Technology.

Furthermore, life sciences also stand out as a major highlight on the list, covering areas such as gene editing, new drug development, pharmaceutical professional services, medical devices, and medical equipment. Companies including WuXi AppTec, Fosun Kite Biotechnology, and CytoNiche Biotechnology are all featured on the list.

As a company applying AI technology in the medical field, Tuma Shenwei has been selected as one of the 50 Smartest Companies, demonstrating leadership in technological innovation, service innovation, and business model innovation.

Tumai Shenwei’s vision is to leverage cutting-edge deep learning technologies to propel medicine into the era of artificial intelligence. We have witnessed the industry’s skepticism and resistance toward AI, as well as its subsequent openness and acceptance. Throughout this transition, Tumai Shenwei and our peers have made significant contributions. An increasing number of clinicians are embracing AI, which is becoming an indispensable assistant to physicians.

Zhong Xin, Founder and CEO of Deepwise, at the Summit

At the "Global Smart Companies Summit," Zhong Xin, Founder and CEO of Tuma Shenwei, stated that malignant tumors remain a significant factor affecting human survival. He expressed the hope to leverage artificial intelligence technology to facilitate early screening, diagnosis, and treatment of cancer, thereby effectively reducing disease mortality rates and saving families.

Recently, TomoDeep’s independently developed Volumetric Attention algorithm framework won the world championship in the Liver and Tumor Segmentation Challenge (LiTS). Over the past year, we have continued to innovate by optimizing algorithms for our lung cancer products and developing new disease modules (including chest X-ray for pulmonary diseases, mammography, CT for stroke, and CT for liver cancer). Meanwhile, we are also making breakthroughs in the areas of fracture detection, pulmonary diseases, prostate analysis, and pathology.

Tumashenwei’s Volumetric Attention Solution Wins Championship

“Tumai Shenwei is collaborating with nearly 300 hospitals and research institutions worldwide. Its intelligent diagnostic products assist physicians in processing approximately 25,000 clinical cases daily, significantly enhancing diagnostic efficiency while effectively reducing misdiagnosis rates,” emphasized Zhong Xin.

In May this year, the China Intelligent Diagnosis and Treatment Strategy Alliance for Lung Cancer was established at the CMEF in Shanghai. As a key member of the alliance, TomoDeep provides a closed-loop intelligent diagnostic solution throughout the entire process of lung cancer diagnosis and treatment, covering early screening, nodule detection, nodule classification, biopsy guidance, and postoperative follow-up. Currently, TomoDeep’s Intelligent Lung Nodule Diagnostic System (σ-Discover/Lung Nodule) has entered large-scale clinical application at the Pulmonary Nodule Diagnosis and Treatment Sub-center of Shanghai International Medical Center, marking the transition of AI-based lung nodule diagnostic technology from research to clinical practice.

CMEF: Establishment of the China Strategic Alliance for Intelligent Diagnosis and Treatment of Lung Cancer

Emerging technologies are continuously reshaping the world, rapidly shortening the time and distance from laboratory research to commercial deployment. Tumor Deepwise is fulfilling its mission—to integrate deep learning into intelligent healthcare and harness technology for the benefit of humanity.

Tumashenwei, established in 2015, is a high-tech enterprise dedicated to the research and development of world-class intelligent medical imaging computer-aided diagnosis (CAD) systems and comprehensive multi-dimensional solutions. Its current product portfolio encompasses a relatively complete suite of medical imaging CAD products for pulmonary nodules, thoracic diseases, liver diseases, breast cancer, stroke, and brain tumors. The company is committed to applying artificial intelligence and deep learning to multi-region, full-process, and multi-departmental auxiliary diagnosis, while expanding its applications into pathology, genomics, and pharmaceutical scenarios. Tumashenwei’s products have been deployed in over 200 hospitals, and it has established scientific research collaborations with more than 30 leading domestic and international hospitals, achieving initial commercialization. The company is progressively deepening its global footprint, having completed its overseas layout in the United States, Japan, and Europe. By fostering in-depth collaborations with local strategic partners, top-tier research institutions, and hospitals, Tumashenwei aims to further consolidate and strengthen its industry leadership.